

Friday, 6 September 2024 Plenary Room: Paranimf

09:00 - 10:00	Welcome and Introduction Chairs: <i>Anna Sureda (ES), Nico Gagelmann (DE) & Claire Horgan (UK)</i>	
09:00 - 09:15	What is EBMT	Anna Sureda (ES)
09:15 - 09:30	What is WMDA	Lydia Foeken (NL)
09:30 - 09:45	What is JACIE	Bruna Gotardo (ES)
09:45 - 10:00	Q&A	
10:00 - 11:15	Session I: Basics to know Chairs: <i>Daniele Sannipoli (IT) & Mette Hazenberg (NL)</i>	
10:00 - 10:15	HLA-system	Pietro Crivello (DE)
10:15 - 10:30	Role of germline predisposition	Carmelo Curnari (IT)
10:30 - 10:45	Donor selection and graft source	Frédéric Baron (BE)
10:45 - 10:50	Case Presentation 1: CEBPA germinal variant carrier family: Importance of basal genetic studies and donor selection	
10:50 - 11:15	Q&A	Shiomara R. Quiñones (ES)
11:15 - 11:45	Coffee Break	
11:45 - 13:00	Session II: Old but new? Chairs: <i>Esra Gülderen (TR) & Annoek Broers (NL)</i>	
11:45 - 12:00	Conditioning regimen and intensity	Francesca Kinsella (UK)
12:00 - 12:15	Engraftment, graft failure, poor graft function	Annalisa Ruggeri (IT)
12:15 - 12:30	Measurable residual disease	Felicitas Thol (DE)
12:30 - 12:35	Case Presentation 2: A Case of CD19-directed CAR-T Cell Therapy in a Patient with refractory Anti-Jo1-Antisynthetase-Syndrome	Johanna Richter (DE)
12:35 - 12:40	Case Presentation 3 : Re-achievement of MRD negativity in a patient with FLT3-mutated acute myeloid leukemia after HCT	Giulia Furnari (IT)
12:40 - 13:00	Q&A	
13:00 - 13:45	Lunch Break	
13:45 - 14:30	Industry Symposium "30 years of treating GvHD with ECP" by Therakos	
13:45 - 13:50	Introduction	Anna Sureda (ES)
13:50 - 14:20	After using ECP in GvHD for 30 years - does the number of cells treated matter?	Nina Worel (AT)
14:05 - 14:20	ECP as monotherapy or combination option in GvHD patients in the era of personalized medicine	Nicolaus Kröger (DE)
14:20 - 14:30	Discussion	All faculty
14:30 - 16:00	Session III: Statistical and ethical considerations Chairs: <i>Daniele Sannipoli (IT) & Michelle Kenyon (UK)</i>	
14:30 - 14:50	Statistics	Jacques-Emmanuel Galimard (FR)
14:50 - 15:10	Non-relapse mortality from patient perspective	Natacha Bolaños (ES)
15:10 - 15:30	Patient reported outcomes	Anna Barata (US)
15:30 - 15:45	Palliative care: when enough is enough?	Jennifer Vidrine (UK)
15:45 - 16:00	Q&A	



9th International Transplant and Cellular Therapy Course

Preliminary Programme

Barcelona, Spain
6-8 September 2024

16:00 - 16:30 **Coffee Break**

16:30 - 18:00 **Session IV: GVHD**

Chairs: *Gabriele Facchin (IT) & Zinaida Perić (HR)*

16:30 - 16:45 Prophylaxis and diagnosis

Carmen Martinez (ES)

16:45 - 17:00 Treatment of acute GVHD

Giorgia Battipaglia (IT)

17:00 - 17:15 Treatment of chronic GVHD

Zinaida Perić (HR)

17:15 - 17:35 Q&A

17:35 - 17:40 Case presentation 4: Fatal acute graft-versus-host disease in Sezary Syndrome treated with

Mogamulizumab and hematopoietic cell transplantation

Gentiana Elena Trotta (IT)

17:40 - 17:45 Case Presentation 5: New onset dysphagia in a patient affected by chronic GvHD: the importance of differential diagnosis

Maria Helena Parrinello (IT)

17:45 - 18:00 Q&A

18:15 - 19:45 **Poster Tour and Welcome Reception**

Saturday, 7 September 2024
Plenary Room: Paranimf | Adults' track

09:00 - 09:50	Session V: Indications for allogeneic HCT in Adults – MDS and MPN	
	Chairs: <i>Tomasz Czerw (PL) & Kristin Rathje (DE)</i>	
09:00 - 09:25	Introductory Case-based MDS – Discussion	Kristin Rathje (DE) Nicolaus Kröger (DE)
09:25 - 09:50	Introductory Case-based MPN - Discussion	Carolyn Maharaj (UK) Donal McLornan (UK)
09:50 - 10:40	Session VI: Indications for allogeneic HCT in Adults – Leukemia	
	Chairs: <i>Fabio Ciceri (IT) & Vera Radici (IT)</i>	
09:50 - 10:15	Introductory Case-based AML - Discussion	Sam Drummond (UK) Charles Craddock (UK)
10:15 - 10:40	Introductory Case-based ALL - Discussion	Ryszard Swoboda (PL) Sebastian Giebel (PL)
10:40 - 11:10	Coffee Break	
11:10 - 12:30	Session VII: Challenging Cases in allogeneic HCT	
	Chairs: <i>Fabio Ciceri (IT) & Tomasz Czerw (PL)</i>	
	Panellists: <i>Charles Craddock (UK), Nicolaus Kröger (DE) & Donal McLornan (UK) & Sebastian Giebel (PL)</i>	
11:10 - 11:30	Transplant for bone marrow failures	Antonio Risitano (IT)
11:30 - 11:35	Case Presentation 6: Refractory All Requiring CAR-T Cells And Hsct in a Patient with Cystic Fibrosis	Benedetta Elena Di Majo (IT)
11:35 - 11:50	Discussion	
11:50 - 11:55	Case Presentation 7: Donor Cell Myelodysplastic Syndrome after 10 years of related HLA matched Bone Marrow Transplant	Flor Maria Armillas Canseco (MX)
11:55 - 12:10	Discussion	
12:10 - 12:15	Case Presentation 8: Case Presentation 8: Transforming Allo-HCT Eligibility Through Pre-Habilitation: A Case Report of a Patient with Myelodysplastic Syndrome	Ares Guardia (ES)
12:15 - 12:30	Discussion	
12:30 - 13:15	Lunch Break	
13:15 - 14:00	Industry Symposium "Treosulfan as a conditioning agent for allogeneic hematopoietic stem cell transplantation" by medac	
	Your choice for adult patients	Jose A. Pérez Simón (ES)
	A universal agent for pediatric stem cell transplantation	Krzysztof Kałwak (PL)
14:00 - 15:40	Session VIII: Indications for transplant and CAR-T	
	Chairs: <i>Patrick Hayden (IE) & Marion Larue (FR)</i>	
14:00 - 14:15	Multiple myeloma: Transplant	Meral Beksac (TR)
14:15 - 14:30	Multiple myeloma: CAR-T	Nico Gagelmann (DE)
14:30 - 14:35	Case Presentation 9: CAR-T cell for AL amyloidosis: a clinical challenge	Ines Zugasti (ES)
14:35 - 14:50	Q&A	
14:50 - 15:05	Lymphoma: Transplant	Ali Bazarbachi (LB)
15:05 - 15:20	Lymphoma: CAR-T	Alberto Mussetti (ES)
15:20 - 15:25	Case Presentation 10: Refractory hydro vacciniform-like cutaneous T- cell lymphoma secondary to Epstein-Barr virus infection successfully treated with allogeneic hematopoietic stem cell transplantation: A case report	Pedro Valeri (BR)
15:25 - 15:40	Q&A	



9th International Transplant and Cellular Therapy Course

Preliminary Programme

Barcelona, Spain
6-8 September 2024

15:40 - 16:00 **Coffee Break**

16:00 - 17:00 **Keynote Lectures**

Chairs: *Rosamaria Nitti (IT)*

16:00 - 16:20 Current status of autologous HCT in AID

16:20 - 16:40 Novel frontiers: CAR-T in AID

16:40 - 17:00 Q&A

Tobias Alexander (DE)

Raffaella Greco (IT)

Saturday, 7 September 2024 Aula Magna | Paediatrics' track

09:00 - 10:20	Session I: Acute leukaemia in children Chairs: <i>Krzysztof Kałwak (PL) & Claire Horgan (UK)</i> HSCT for AML in 2024- who, how and when? Latest updates for HSCT in Paediatric ALL Challenging cases in paediatric ALL-CAR-T and beyond Case presentation 11: Low disease burden before CAR-T cell infusion highly reduces therapy-related toxicities Q&A and discussion	Claire Horgan (UK) Christina Peters (AT) Krzysztof Kałwak (PL) Paweł Marschollek (PL)
10:40 - 11:10	Coffee Break	
11:10 - 12:30	Session II: Inborn errors of metabolism Chairs: <i>Bénédicte Neven (FR) & Katherine Colman (AU)</i> HSCT vs gene therapy for metabolic disease Stem cell therapy for immune deficiency in 2024 HSCT for immune dysregulation Case presentation 12: Successful immune-tolerance achieved in patient with Schimke immune-osseous dysplasia (SIOD) using sequential approach of Reduced intensity conditioned Haploidentical HSCT ($\alpha\beta$ T cell and CD19 B cell depleted) followed by live-related renal transplant from same donor. Discussion	Valeria Calbi (IT) Bénédicte Neven (FR) Bénédicte Neven (FR) Archana Rauthan (UK)
12:30 - 13:15	Lunch Break	
13:15 - 14:00	Industry Symposium "Treo sulfan as a conditioning agent for allogeneic hematopoietic stem cell transplantation" by medac in Paranimf room Your choice for adult patients A universal agent for pediatric stem cell transplantation	Jose A. Pérez Simón (ES) Krzysztof Kałwak (PL)
14:00 - 15:30	Session III: Haemoglobinopathies and bone marrow failure syndromes Chairs: <i>Emanuele Angelucci (IT) & Manuela Spadea (IT)</i> HSCT vs gene therapy for haemoglobinopathy Case-based approach to HSCT for congenital bone marrow failure syndromes HSCT for paediatric MDS in 2024- who, how and when? Case presentation 13: Mismatched sibling T Cell Receptor alpha/beta depleted myeloablative transplantation in a patient with recurrent hyperhaemolysis and multiple sickle cell disease related comorbidities – a challenge Discussion	Emanuele Angelucci (IT) Carlo Dufour (IT) Brigitte Strahm (DE) Akshay Deshpande (UK)

Sunday, 8 September 2024
Plenary Room: Paranimf

09:00 - 10:30	Session IX: Endothelial and neurologic complications after HCT Chairs: <i>Mustafa Güven (TR) & Giorgio Orofino (IT)</i>	
09:00 - 09:15	VOD	Mohamad Mohty (FR)
09:15 - 09:30	TMA	Rafael Duarte (ES)
09:30 - 09:45	Neurological complications (non-infectious)	Lars Kligen Gjørde (DK)
09:45 - 10:00	Q&A	
10:00 - 10:15	Long-term complications	Michelle Kenyon (UK)
10:15 - 10:20	Case Presentation 14: Thinking outside the box: differential diagnosis between VOD and PTCy toxicity	Francesca Mazzocco (IT)
10:20 - 10:30	Q&A	
10:30 - 11:00	Coffee Break	
11:00 - 12:30	Session X: Infections Chairs: <i>Alexandra Martinez (ES) & Jan Styczyński (PL)</i>	
11:00 - 11:15	CMV	Jan Styczyński (PL)
11:15 - 11:30	Other Herpesviridae	Jose Luis Piñana (ES)
11:30 - 11:45	Fungal	Maya Korem (IL)
11:45 - 11:50	Case Presentation 15: SARS-COV-2 and dengue virus co-Infection during Cytomegalovirus Preemptive Treatment after Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: A Brazilian Case Report	Noemi Lira (BR)
11:50 - 12:10	Q&A	
12:10 - 13:15	Session XI: Complications after CAR-T Chairs: <i>Anna Sureda (ES), Krzysztof Kalwak (PL)</i>	
12:10 - 12:25	CRS & ICANS	Roberta Di Blasi (FR)
12:25 - 12:40	HLH & MAS	Matteo Doglio (IT)
12:40 - 12:45	Critical care management of BMT/CAR-T patients	Pedro Castro (ES)
12:45 - 13:00	Q&A	
13:15 - 13:30	Closing and Poster Awards	